The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic heteroaryl, which may independently substituted by alkyl or amino； B is selected from alkyl, heteroalkyl, alkyl-amino, aryl, heteroaryl, cycloalkyl, heterocyclyl and alkylene, wherein said groups may independently be substituted by alkyl； D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide, sulfoximine and sulfamoyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted； and E is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted. The compounds of formula (I) are inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N- terminal glutamate residues into pyroglutamic acid under liberation of water.L'invention concerne un composé de formule (I) : A-B-D-E (I) ou un sel, solvate ou polymorphe pharmaceutiquement acceptable de celui-ci, comprenant tous les tautomères et stéréoisomères de celui-ci. Dans la formule, A est choisi parmi hétéroaryle monocyclique et bicyclique, qui peut être substitué indépendamment par un alkyle ou amino ； B est choisi parmi alkyle, hétéroalkyle, alkyle-amino, aryle, hétéroaryle, cycloalkyle, hétérocyclyle et alkylène, lesdits groupes pouvant être indépendamment substitués par alkyle ； D est choisi parmi aryle-amino, hétéroaryle-amino, cycloalkyle-amino, hétérocyclyle, hétérocyclyle-amino, urée, thioamide, thiourée, sulfonamide, sulfoximine et sulfamoyle, lesdits groupes aryle, hétéroaryle, cycloal
